X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13) 13
oncology (12) 12
humans (9) 9
male (9) 9
middle aged (9) 9
aged (8) 8
female (7) 7
metastasis (7) 7
adult (6) 6
carcinoma, non-small-cell lung - drug therapy (6) 6
care and treatment (6) 6
lung cancer, non-small cell (6) 6
lung neoplasms - drug therapy (6) 6
patients (6) 6
aged, 80 and over (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
cancer (5) 5
chemotherapy (5) 5
nivolumab (5) 5
therapy (5) 5
treatment outcome (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
bevacizumab (4) 4
clinical trials (4) 4
disease-free survival (4) 4
lung cancer (4) 4
lung neoplasms - pathology (4) 4
medicine, general & internal (4) 4
respiratory system (4) 4
survival (4) 4
antimitotic agents (3) 3
antineoplastic agents (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
docetaxel (3) 3
double-blind method (3) 3
drug administration schedule (3) 3
ligands (3) 3
metastases (3) 3
non-small-cell lung cancer (3) 3
nsclc (3) 3
pd-l1 protein (3) 3
safety (3) 3
analysis (2) 2
anaplastic lymphoma kinase - genetics (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antineoplastic agents - administration & dosage (2) 2
apoptosis (2) 2
article (2) 2
b7-h1 antigen - metabolism (2) 2
body weight (2) 2
cancer therapies (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
carcinoma, non-small-cell lung - secondary (2) 2
carcinoma, squamous cell - drug therapy (2) 2
cell survival (2) 2
clear cell-type renal cell carcinoma (2) 2
clinical-trials (2) 2
egfr mutation (2) 2
hematology, oncology and palliative medicine (2) 2
histology (2) 2
immune checkpoint (2) 2
immunotherapy (2) 2
indoles - administration & dosage (2) 2
indoles - adverse effects (2) 2
kaplan-meier estimate (2) 2
kidney cancer (2) 2
kras mutation (2) 2
life span (2) 2
lipase (2) 2
lung neoplasms - mortality (2) 2
medical colleges (2) 2
molecular targeted therapy (2) 2
motivation (2) 2
multicenter (2) 2
mutation (2) 2
mutations (2) 2
neoplasm staging (2) 2
neutrophils (2) 2
niacinamide - analogs & derivatives (2) 2
non-small cell lung carcinoma (2) 2
pd-1 protein (2) 2
pembrolizumab (2) 2
phase-iii trial (2) 2
placebos (2) 2
platinum (2) 2
solid tumors (2) 2
sorafenib (2) 2
sunitinib (2) 2
survival analysis (2) 2
survival rate (2) 2
taxoids - administration & dosage (2) 2
tumors (2) 2
1st-line treatment (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - secondary (1) 1
adenocarcinoma of lung - diagnosis (1) 1
adenocarcinoma of lung - epidemiology (1) 1
adenocarcinoma of lung - genetics (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 2, pp. 123 - 135
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10066, pp. 255 - 265
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 760 - 768
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
The Lancet Oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1468 - 1479
Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer... 
SURVIVAL | MULTICENTER | PEMBROLIZUMAB | MICROENVIRONMENT | NSCLC | ONCOLOGY | ATEZOLIZUMAB | NIVOLUMAB | ETHNICITY | Antimitotic agents | Care and treatment | Lung cancer, Non-small cell | Antineoplastic agents | Analysis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 11, pp. 1835 - 1842
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Genes, erbB-1 - drug effects | Lung Neoplasms - drug therapy | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - metabolism | Middle Aged | Far East - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Anaplastic Lymphoma Kinase - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Lung Neoplasms - secondary | Female | Carcinoma, Non-Small-Cell Lung - pathology | Anaplastic Lymphoma Kinase - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Genes, erbB-1 - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Disease-Free Survival | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Slopes | Lung cancer | Oncology | Kinases | Cancer therapies | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Hypothyroidism | Survival | Patients | Medical centres | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Tumors | Apoptosis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 8, pp. 765 - 772
PurposeCabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival... 
TARGETED THERAPY | SURVIVAL | IMPACT | EVEROLIMUS | ONCOLOGY | GROWTH | SUNITINIB | ORIGINAL REPORTS
Journal Article